# Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

> **NCT00092716** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 655 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** MK0653, ezetimibe / Duration of Treatment: 28 weeks
- **DRUG:** Comparator: atorvastatin / Duration of Treatment: 28 weeks

## Key facts

- **NCT ID:** NCT00092716
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** 655 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092716, "Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00092716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*